A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects

Yang, Xin-Mei; Yang, Yang; Yao, Bu-Fan; Ye, Pan-Pan; Xu, Yan; Peng, Shao-Ping; Yang, Yu-Mei; Shu, Pan; Li, Pei-Jin; Li, Shan; Hu, Hong-Lin; Li, Qian; Song, Lin-Lin; Chen, Ke-Guang; Zhou, Hai-Yan; Zhang, Ye-Hui; Zhao, Fu-Rong; Tang, Bo-Hao; Zhang, Wei; Zhang, Xin-Fang; Fu, Shu-Meng; Hao, Guo-Xiang; Zheng, Yi; Shen, Jing-Shan; Xu, Ye-Chun; Jiang, Xiang-Rui; Zhang, Lei-Ke; Tang, Ren-Hong; Zhao, Wei

Published in

Elsevier, European Journal of Pharmaceutical Sciences, p. 106598, 2023

DOI: 10.1016/j.ejps.2023.106598

Tools

Export citation

Search in Google Scholar

A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects

Journal article published in 2023 by Xin-Mei Yang, Yang Yang, Bu-Fan Yao, Pan-Pan Ye, Yan Xu, Shao-Ping Peng, Yu-Mei Yang, Pan Shu, Pei-Jin Li, Shan Li, Hong-Lin Hu, Qian Li, Lin-Lin Song, Ke-Guang Chen, Hai-Yan Zhou and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving allowed

Upload

Policy details

Data provided by

Published in

Links

Tools

A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects